Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Siena M. Mantooth"'
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Breast cancer poses one of the largest threats to women’s health. Treatment continues to improve for all the subtypes of breast cancer, but some subtypes, such as triple negative breast cancer, still present a significant treatment challenge. Addit
Externí odkaz:
https://doaj.org/article/33b4661abaa846989ebd08a2afcea688
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Despite the remarkable efficacy of currently approved COVID-19 vaccines, there are several opportunities for continued vaccine development against SARS-CoV-2 and future lethal respiratory viruses. In particular, restricted vaccine access and hesitanc
Externí odkaz:
https://doaj.org/article/1c9518ab0709457d94cc77dc77d7346b
Autor:
Khue G. Nguyen, Maura R. Vrabel, Siena M. Mantooth, Jared J. Hopkins, Ethan S. Wagner, Taylor A. Gabaldon, David A. Zaharoff
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Interleukin-12 (IL-12) is a potent, pro-inflammatory type 1 cytokine that has long been studied as a potential immunotherapy for cancer. Unfortunately, IL-12's remarkable antitumor efficacy in preclinical models has yet to be replicated in humans. Ea
Externí odkaz:
https://doaj.org/article/2a102ed6a77f4157aa4fd7e3ad96d718
Autor:
Maura R. Vrabel, Jacob A. Schulman, Francis B. Gillam, Siena M. Mantooth, Khue G. Nguyen, David A. Zaharoff
Publikováno v:
Cancers; Volume 15; Issue 8; Pages: 2210
Focal ablation technologies are routinely used in the clinical management of inoperable solid tumors but they often result in incomplete ablations leading to high recurrence rates. Adjuvant therapies, capable of safely eliminating residual tumor cell
Safety and Pharmacokinetics of Intravesical Chitosan/Interleukin-12 Immunotherapy in Murine Bladders
Autor:
Maura R. Vrabel, Khue G. Nguyen, Siena M. Mantooth, Ethan S. Wagner, David A. Zaharoff, Danielle M. Meritet
Publikováno v:
Bladder Cancer. 7:427-437
BACKGROUND: Intravesical administration of interleukin 12 (IL-12) co-formulated with the biopolymer, chitosan (CS/IL-12), has demonstrated remarkable antitumor activity against preclinical models of bladder cancer. However, given historical concerns
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundUnresectable solid malignancies are responsible for a major proportion of total cancer-related mortalities, making focal ablation an attractive alternative. Nevertheless, there are high rates of recurrence after ablation [1,2]. The addition
Autor:
Maura R. Vrabel, Khue G. Nguyen, David A. Zaharoff, Taylor A. Gabaldon, Ethan S. Wagner, Jared J. Hopkins, Siena M. Mantooth
Publikováno v:
Frontiers in Immunology
Frontiers in Immunology, Vol 11 (2020)
Frontiers in Immunology, Vol 11 (2020)
Interleukin-12 (IL-12) is a potent, pro-inflammatory type 1 cytokine that has long been studied as a potential immunotherapy for cancer. Unfortunately, IL-12's remarkable antitumor efficacy in preclinical models has yet to be replicated in humans. Ea
Publikováno v:
Macromolecular bioscience. 19(1)
Hydrogel biomaterials are pervasive in biomedical use. Applications of these soft materials range from contact lenses to drug depots to scaffolds for transplanted cells. A subset of hydrogels is prepared from physical cross-linking mediated by host-g